Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies

Background: Tigecycline and cefoperazone/sulbactam can cause coagulation disorders; tigecycline may also lead to hypofibrinogenemia, raising safety concerns. This study aimed to investigate whether tigecycline plus cefoperazone/sulbactam increases the risk of bleeding compared with other tigecycline...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lei, Cai, Xinfeng, Peng, Fangchen, Tian, Shuangshuang, Wu, Xinjing, Li, Yun, Guo, Jinlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282135/
https://www.ncbi.nlm.nih.gov/pubmed/37351509
http://dx.doi.org/10.3389/fphar.2023.1182644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282135/
https://www.ncbi.nlm.nih.gov/pubmed/37351509
http://dx.doi.org/10.3389/fphar.2023.1182644

Ejemplares similares